Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Articular Bleeding in Hemophilia.

Rodriguez-Merchan EC.

Cardiovasc Hematol Disord Drug Targets. 2016;16(1):21-24. Review.

PMID:
28049407
2.

Prevention of bleeding in hemophilia patients with high-titer inhibitors.

Leissinger CA, Konkle BA, Antunes SV.

Expert Rev Hematol. 2015 Jun;8(3):375-82. doi: 10.1586/17474086.2015.1036733. Epub 2015 May 2. Review.

PMID:
25937074
3.

A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.

Mehta DA, Oladapo AO, Epstein JD, Novack AR, Neufeld EJ, Hay JW.

J Manag Care Spec Pharm. 2016 Feb;22(2):149-57. doi: 10.18553/jmcp.2016.22.2.149.

4.

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.

Chai-Adisaksopha C, Nevitt SJ, Simpson ML, Janbain M, Konkle BA.

Cochrane Database Syst Rev. 2017 Sep 25;9:CD011441. doi: 10.1002/14651858.CD011441.pub2. Review.

PMID:
28944952
5.

Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis.

Zhou ZY, Hay JW.

Clin Ther. 2012 Feb;34(2):434-45. doi: 10.1016/j.clinthera.2012.01.001. Epub 2012 Jan 27. Review.

PMID:
22285208
6.

Management and prevention of recurrent hemarthrosis in patients with hemophilia.

Dunn AL.

Curr Opin Hematol. 2005 Sep;12(5):390-4. Review.

PMID:
16093785
7.

Hemophilic arthropathy of the elbow: prophylaxis, imaging, and the role of invasive management.

Dale TM, Saucedo JM, Rodríguez-Merchán EC.

J Shoulder Elbow Surg. 2015 Oct;24(10):1669-78. doi: 10.1016/j.jse.2015.06.018. Review.

PMID:
26385390
8.

Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.

Steen Carlsson K, Astermark J, Donfield S, Berntorp E.

Thromb Haemost. 2008 Jun;99(6):1060-7. doi: 10.1160/TH07-11-0698.

PMID:
18521509
9.

The long-term effects of radioactive phosphorous synoviorthesis on hemophilic arthropathy.

Eraghi AS, Kaseb MH, Espandar R, Mardookhpour S.

Blood Cells Mol Dis. 2015 Jun;55(1):68-70. doi: 10.1016/j.bcmd.2015.03.011. Epub 2015 Mar 30.

PMID:
25976470
10.

The target joint.

Mulder K, Llinás A.

Haemophilia. 2004 Oct;10 Suppl 4:152-6. Review.

PMID:
15479389
11.

Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.

Villarrubia R, Oyagüez I, Álvarez-Román MT, Mingot-Castellano ME, Parra R, Casado MA.

Haemophilia. 2015 May;21(3):320-9. doi: 10.1111/hae.12681. Epub 2015 Apr 9.

PMID:
25855214
12.
13.

Orthopedic management of hemophilia.

Heyworth BE, Su EP, Figgie MP, Acharya SS, Sculco TP.

Am J Orthop (Belle Mead NJ). 2005 Oct;34(10):479-86. Review.

PMID:
16304795
14.

Treatment of hemophilia.

Rodeghiero F.

Ric Clin Lab. 1985 Oct-Dec;15(4):289-303. Review.

PMID:
3914697
15.

Experiences in the prevention of arthropathy in haemophila patients with inhibitors.

Jimenez-Yuste V, Rodriguez-Merchan EC, Alvarez MT, Quintana M, Martin-Salces M, Hernandez-Navarro F.

Haemophilia. 2008 Nov;14 Suppl 6:28-35. doi: 10.1111/j.1365-2516.2008.01887.x. Review.

PMID:
19134031
16.

Prophylaxis in haemophilia with inhibitors: update from international experience.

Carcao M, Lambert T.

Haemophilia. 2010 Mar;16 Suppl 2:16-23. doi: 10.1111/j.1365-2516.2009.02198.x.

PMID:
20132334
17.

Rheumatological management of patients with hemophilia. Part 1: joint manifestations.

Alcalay M, Deplas A.

Joint Bone Spine. 2002 Oct;69(5):442-9. Review.

PMID:
12477227
18.
19.

Hemophilic arthropathy.

Luck JV Jr, Silva M, Rodriguez-Merchan EC, Ghalambor N, Zahiri CA, Finn RS.

J Am Acad Orthop Surg. 2004 Jul-Aug;12(4):234-45. Review.

PMID:
15473675
20.

Management of joint bleeding in hemophilia.

Simpson ML, Valentino LA.

Expert Rev Hematol. 2012 Aug;5(4):459-68. Review.

PMID:
22992238

Supplemental Content

Support Center